Chikungunya (CHIKV) Infection Drug Development Pipeline Study, H2 2018
Chikungunya (CHIKV) Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Chikungunya (CHIKV) Infection pipeline products.
DISEASE OVERVIEW
Chikungunya fever is a viral fever, caused by Chikungunya virus (CHIKV), which belongs to the family%li%Togaviridae. It is spread through Aedes species mosquito bites from infected person to healthy person.
Fever and joint pains are the primary symptoms while headache, muscle aches, swelling in joints and rashes are also found in patients infected with chikungunya fever.
Over the recent few years, mass outbreaks of the chikungunya infection are observed in Africa, Europe, Asia and Oceania. Currently, no treatment options or vaccines have been developed to treat/ prevent chikungunya virus infection.
To gain from the unmet demand for Chikungunya, 25+ companies are currently actively developing vaccines and treatment options. It is one of the most researched areas in infectious diseases with 25 therapeutic candidates in various stages of pre-clinical and clinical pipeline phases.
Companies participating in Chikungunya virus infection pipeline development include%li%Bharat Biotech International Ltd, Ciloa, Ennaid Therapeutics LLC, Globavir Biosciences Inc, HSRx Group, Inovio Pharmaceuticals Inc, Integral Molecular Inc, Integrated BioTherapeutics Inc, Moderna Therapeutics Inc, Mymetics Corp, Najit Technologies, Paradigm Biopharmaceuticals Ltd, PaxVax Inc, Profectus BioSciences Inc, Riboscience LLC, Sementis Ltd, Singapore Immunology Network, Sun Pharmaceutical Industries, Takeda Pharmaceutical Co Ltd, Themis Bioscience GmbH, Valneva SE and Vaxart.
REPORT DESCRIPTION
The Chikungunya (CHIKV) Infection pipeline guide presents complete overview of drugs currently being developed for Chikungunya (CHIKV) Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Chikungunya (CHIKV) Infection pipeline candidate.
Research and Development progress along with latest news related to each of the Chikungunya (CHIKV) Infection pipeline candidates is included.
Major companies participating in therapeutic development of Chikungunya (CHIKV) Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Chikungunya (CHIKV) Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Chikungunya (CHIKV) Infection clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Chikungunya (CHIKV) Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF CHIKUNGUNYA (CHIKV) INFECTION PIPELINE REPORT INCLUDES
DISEASE OVERVIEW
Chikungunya fever is a viral fever, caused by Chikungunya virus (CHIKV), which belongs to the family%li%Togaviridae. It is spread through Aedes species mosquito bites from infected person to healthy person.
Fever and joint pains are the primary symptoms while headache, muscle aches, swelling in joints and rashes are also found in patients infected with chikungunya fever.
Over the recent few years, mass outbreaks of the chikungunya infection are observed in Africa, Europe, Asia and Oceania. Currently, no treatment options or vaccines have been developed to treat/ prevent chikungunya virus infection.
To gain from the unmet demand for Chikungunya, 25+ companies are currently actively developing vaccines and treatment options. It is one of the most researched areas in infectious diseases with 25 therapeutic candidates in various stages of pre-clinical and clinical pipeline phases.
Companies participating in Chikungunya virus infection pipeline development include%li%Bharat Biotech International Ltd, Ciloa, Ennaid Therapeutics LLC, Globavir Biosciences Inc, HSRx Group, Inovio Pharmaceuticals Inc, Integral Molecular Inc, Integrated BioTherapeutics Inc, Moderna Therapeutics Inc, Mymetics Corp, Najit Technologies, Paradigm Biopharmaceuticals Ltd, PaxVax Inc, Profectus BioSciences Inc, Riboscience LLC, Sementis Ltd, Singapore Immunology Network, Sun Pharmaceutical Industries, Takeda Pharmaceutical Co Ltd, Themis Bioscience GmbH, Valneva SE and Vaxart.
REPORT DESCRIPTION
The Chikungunya (CHIKV) Infection pipeline guide presents complete overview of drugs currently being developed for Chikungunya (CHIKV) Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Chikungunya (CHIKV) Infection pipeline candidate.
Research and Development progress along with latest news related to each of the Chikungunya (CHIKV) Infection pipeline candidates is included.
Major companies participating in therapeutic development of Chikungunya (CHIKV) Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Chikungunya (CHIKV) Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Chikungunya (CHIKV) Infection clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Chikungunya (CHIKV) Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF CHIKUNGUNYA (CHIKV) INFECTION PIPELINE REPORT INCLUDES
- Panorama of Chikungunya (CHIKV) Infection pipeline markets including statistics on therapeutic drugs and companies involved
- Chikungunya (CHIKV) Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
- Chikungunya (CHIKV) Infection pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
- Overview of companies participating in Chikungunya (CHIKV) Infection pipeline with short introduction to their businesses and pipeline projects
- For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
- Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Chikungunya (CHIKV) Infection pipeline therapeutics
- Get clear understanding of the entire Chikungunya (CHIKV) Infection pipeline, with details on active projects
- Get in detail information of each product with updated information on each project along with key milestones
- Know the list of companies participating in global Chikungunya (CHIKV) Infection pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
I. KEY FINDINGS
1. Companies Investing in Chikungunya Infection Pipeline include-
Number of Companies with Chikungunya Infection projects in pre-clinical Development-
Number of Companies with Chikungunya Infection projects in Clinical Development-
Chikungunya Infection Pipeline Companies based in Americas
Chikungunya Infection Pipeline Companies based in Europe
Chikungunya Infection Pipeline Companies based in Asia Pacific
Chikungunya Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Chikungunya Infection Pipeline Agents in pre- clinical/Discovery stage of Development
Chikungunya Infection Pipeline Agents in Clinical Development stage
Chikungunya Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Chikungunya Infection Pipeline agents
II. INSIGHTS INTO CHIKUNGUNYA INFECTION PIPELINE
1. Disease Overview
Introduction to Chikungunya Infection
Symptoms and Causes of Chikungunya Infection
Treatment or Prevention Options for Chikungunya Infection
Other Details
2. Phase wise Pipeline Compounds
Chikungunya Infection Pipeline- Pre- Clinical/Discovery stage Drugs
Chikungunya Infection Pipeline- Phase 1 stage Drugs
Chikungunya Infection Pipeline- Phase 2 stage Drugs
Chikungunya Infection Pipeline- Phase 3 stage Drugs
Chikungunya Infection Pipeline- Pre-Registration stage Drugs
3. Company wise Chikungunya Infection Pipeline Compounds
4. Chikungunya Infection Pipeline by Mechanism of Action
III. CHIKUNGUNYA INFECTION PIPELINE COMPOUND DETAILS
chikungunya virus vaccine
anti-viral peptide for Chikungunya
GBV006
HSRx
chikungunya vaccine
CHIKV-dmAb
IM-CKV063
neutralizing antibodies for Equine Encephalitis viruses and Chikungunya
mRNA-1388
mRNA-1944
CHIKV vaccine
Chikungunya virus vaccine(Najit/ABL)
Pentosan Polysulfate
Chikungunya VLP Vaccine
VesiculoVax-vectored vaccine
nucleoside analogs for the treatment of Dengue, Ebola, Chikungunya and Zika virus
dual acting vaccine(SCV1002)
SCV305
SIgN Human Monoclonal Antibody
antiviral therapeutics
TAK-507
Chikungunya virus vaccine(MV-CHIK)
VLA 1553
oral vaccine against Chikungunya Virus
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. CHIKUNGUNYA INFECTION PIPELINE COMPANY BRIEFS
Bharat Biotech International Ltd
Ciloa SAS
Ennaid Therapeutics LLC
Globavir Biosciences Inc
HSRx Group
Inovio Pharmaceuticals Inc
Integral Molecular Inc
Integrated BioTherapeutics Inc
Moderna Therapeutics Inc
Mymetics Corporation
Najit Technologies Inc
Paradigm Biopharmaceuticals Ltd
PaxVax Inc
Profectus BioSciences Inc
Riboscience LLC
Sementis Ltd
Sun Pharmaceutical Industries Ltd
Takeda Pharmaceutical Co Ltd
Themis Bioscience GmbH
Valneva SE
Vaxart Inc
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL CHIKUNGUNYA INFECTION PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
1. Companies Investing in Chikungunya Infection Pipeline include-
Number of Companies with Chikungunya Infection projects in pre-clinical Development-
Number of Companies with Chikungunya Infection projects in Clinical Development-
Chikungunya Infection Pipeline Companies based in Americas
Chikungunya Infection Pipeline Companies based in Europe
Chikungunya Infection Pipeline Companies based in Asia Pacific
Chikungunya Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Chikungunya Infection Pipeline Agents in pre- clinical/Discovery stage of Development
Chikungunya Infection Pipeline Agents in Clinical Development stage
Chikungunya Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Chikungunya Infection Pipeline agents
II. INSIGHTS INTO CHIKUNGUNYA INFECTION PIPELINE
1. Disease Overview
Introduction to Chikungunya Infection
Symptoms and Causes of Chikungunya Infection
Treatment or Prevention Options for Chikungunya Infection
Other Details
2. Phase wise Pipeline Compounds
Chikungunya Infection Pipeline- Pre- Clinical/Discovery stage Drugs
Chikungunya Infection Pipeline- Phase 1 stage Drugs
Chikungunya Infection Pipeline- Phase 2 stage Drugs
Chikungunya Infection Pipeline- Phase 3 stage Drugs
Chikungunya Infection Pipeline- Pre-Registration stage Drugs
3. Company wise Chikungunya Infection Pipeline Compounds
4. Chikungunya Infection Pipeline by Mechanism of Action
III. CHIKUNGUNYA INFECTION PIPELINE COMPOUND DETAILS
chikungunya virus vaccine
anti-viral peptide for Chikungunya
GBV006
HSRx
chikungunya vaccine
CHIKV-dmAb
IM-CKV063
neutralizing antibodies for Equine Encephalitis viruses and Chikungunya
mRNA-1388
mRNA-1944
CHIKV vaccine
Chikungunya virus vaccine(Najit/ABL)
Pentosan Polysulfate
Chikungunya VLP Vaccine
VesiculoVax-vectored vaccine
nucleoside analogs for the treatment of Dengue, Ebola, Chikungunya and Zika virus
dual acting vaccine(SCV1002)
SCV305
SIgN Human Monoclonal Antibody
antiviral therapeutics
TAK-507
Chikungunya virus vaccine(MV-CHIK)
VLA 1553
oral vaccine against Chikungunya Virus
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. CHIKUNGUNYA INFECTION PIPELINE COMPANY BRIEFS
Bharat Biotech International Ltd
Ciloa SAS
Ennaid Therapeutics LLC
Globavir Biosciences Inc
HSRx Group
Inovio Pharmaceuticals Inc
Integral Molecular Inc
Integrated BioTherapeutics Inc
Moderna Therapeutics Inc
Mymetics Corporation
Najit Technologies Inc
Paradigm Biopharmaceuticals Ltd
PaxVax Inc
Profectus BioSciences Inc
Riboscience LLC
Sementis Ltd
Sun Pharmaceutical Industries Ltd
Takeda Pharmaceutical Co Ltd
Themis Bioscience GmbH
Valneva SE
Vaxart Inc
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL CHIKUNGUNYA INFECTION PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
